Clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
Ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
(	O
A	O
-	O
T	O
)	O
is	O
a	O
recessive	O
multi	O
-	O
system	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	B-DISEASE
The	O
risk	O
of	O
cancer	B-DISEASE
,	O
especially	O
lymphoid	O
neoplasias	O
,	O
is	O
substantially	O
elevated	O
in	O
A	O
-	O
T	O
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	B-DISEASE
instability	I-DISEASE
By	O
analysing	O
tumour	O
DNA	O
from	O
patients	O
with	O
sporadic	O
T	O
-	O
cell	O
prolymphocytic	O
leukaemia	O
(	O
T	O
-	O
PLL	O
)	O
,	O
a	O
rare	O
clonal	O
malignancy	B-DISEASE
Myotonic	B-DISEASE
dystrophy	I-DISEASE
Myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
,	O
the	O
most	O
prevalent	O
muscular	O
disorder	O
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B-DISEASE
Constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	O
retinoblastoma	B-DISEASE
In	O
most	O
patients	O
with	O
isolated	O
unilateral	O
retinoblastoma	B-DISEASE
,	O
tumor	B-DISEASE
However	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B-DISEASE
To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	O
retinoblastoma	B-DISEASE
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	B-DISEASE
The	O
analysis	O
of	O
tumors	B-DISEASE
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	B-DISEASE
For	O
39	O
randomly	O
selected	O
tumors	B-DISEASE
Mutations	O
were	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
23	O
tumors	B-DISEASE
In	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	B-DISEASE
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B-DISEASE
Thus	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	B-DISEASE
Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	B-DISEASE
The	O
presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	B-DISEASE
In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	O
showed	O
multifocal	O
tumors	B-DISEASE
and	O
the	O
other	O
later	O
developed	O
bilateral	O
retinoblastoma	B-DISEASE
In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B-DISEASE
The	O
proband	O
,	O
a	O
20	O
-	O
year	O
-	O
old	O
black	O
female	O
with	O
systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
since	O
age	O
11	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	B-DISEASE
Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	B-DISEASE
of	O
lupus	B-DISEASE
A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	B-DISEASE
Further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	O
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	B-DISEASE
Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	B-DISEASE
,	O
vasculitis	B-DISEASE
,	O
and	O
arthritis	B-DISEASE
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	B-DISEASE
infections	I-DISEASE
Other	O
observations	O
indicate	O
that	O
the	O
C5D	O
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	B-DISEASE
during	O
pyogenic	O
infection	B-DISEASE
Susceptibility	O
to	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
in	O
twins	B-DISEASE
OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B-DISEASE
spondylitis	I-DISEASE
METHODS	O
Twins	B-DISEASE
with	O
AS	O
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	B-DISEASE
Diseases	I-DISEASE
Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	B-DISEASE
Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	B-DISEASE
RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	B-DISEASE
Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	B-DISEASE
disease	B-DISEASE
onset	O
and	O
all	O
of	O
the	O
disease	B-DISEASE
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	B-DISEASE
-	O
concordant	O
MZ	O
twins	B-DISEASE
compared	O
with	O
concordant	O
DZ	O
twins	B-DISEASE
HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	B-DISEASE
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	B-DISEASE
CONCLUSION	O
Susceptibility	O
to	O
AS	O
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	B-DISEASE
Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	O
and	O
ovarian	B-DISEASE
cancer	I-DISEASE
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B-DISEASE
This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1	O
-	O
mediated	O
tumor	B-DISEASE
Recent	O
studies	O
have	O
shown	O
that	O
hereditary	B-DISEASE
hemochromatosis	I-DISEASE
The	O
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
HH	O
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B-DISEASE
Autosomal	O
dominant	O
neurohypophyseal	O
diabetes	B-DISEASE
insipidus	I-DISEASE
Autosomal	O
dominant	O
neurohypophyseal	O
diabetes	B-DISEASE
insipidus	I-DISEASE
(	O
ADNDI	O
)	O
is	O
an	O
inherited	O
disease	B-DISEASE
Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	B-DISEASE
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B-DISEASE
insipidus	I-DISEASE
at	B-DISEASE
The	O
genetic	O
locus	O
of	O
the	O
disease	B-DISEASE
An	O
affected	O
girl	O
who	O
presented	O
at	B-DISEASE
Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B-DISEASE
cancer	I-DISEASE
Sporadic	O
prostate	O
carcinoma	B-DISEASE
is	O
the	O
most	O
common	O
male	O
cancer	B-DISEASE
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B-DISEASE
Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	O
prostate	B-DISEASE
cancer	I-DISEASE
A	O
new	O
tumor	B-DISEASE
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	B-DISEASE
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	B-DISEASE
cancer	I-DISEASE
We	O
screened	O
80	O
prostate	O
tumors	B-DISEASE
The	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B-DISEASE
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	O
prostate	B-DISEASE
cancer	I-DISEASE
Risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B-DISEASE
disease	I-DISEASE
The	O
first	O
predictive	O
testing	O
for	O
Huntington	B-DISEASE
disease	I-DISEASE
Low	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
breast	O
/	O
ovarian	B-DISEASE
cancer	I-DISEASE
In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	O
/	O
ovarian	B-DISEASE
cancer	I-DISEASE
We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B-DISEASE
cancer	I-DISEASE
families	O
and	O
in	O
one	O
breast	B-DISEASE
-	I-DISEASE
ovarian	I-DISEASE
cancer	I-DISEASE
8	O
%	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	B-DISEASE
The	O
average	O
age	O
of	O
disease	B-DISEASE
These	O
findings	O
show	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	O
/	O
ovarian	B-DISEASE
cancer	I-DISEASE
Paternal	O
transmission	O
of	O
congenital	B-DISEASE
myotonic	I-DISEASE
dystrophy	I-DISEASE
We	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	B-DISEASE
myotonic	I-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
The	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	O
retarded	O
male	O
who	O
suffers	O
severe	O
muscular	B-DISEASE
weakness	I-DISEASE
He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	B-DISEASE
His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	B-DISEASE
Their	O
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B-DISEASE
Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B-DISEASE
DM	B-DISEASE
We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B-DISEASE
DM	B-DISEASE
Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	B-DISEASE
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B-DISEASE
DM	B-DISEASE
Also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B-DISEASE
DM	B-DISEASE
We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B-DISEASE
DM	B-DISEASE
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B-DISEASE
The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	O
intracranial	O
retinoblastoma	B-DISEASE
The	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	O
intracranial	O
retinoblastoma	B-DISEASE
The	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	B-DISEASE
Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	B-DISEASE
fibroblasts	O
and	O
melanoma	B-DISEASE
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	O
of	O
hex	O
A	O
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
with	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
The	O
tumor	B-DISEASE
Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumor	B-DISEASE
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	O
cancers	B-DISEASE
Growth	B-DISEASE
retardation	I-DISEASE
Prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B-DISEASE
The	O
French	O
Familial	O
Melanoma	B-DISEASE
Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	B-DISEASE
We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
French	O
melanoma	B-DISEASE
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	B-DISEASE
In	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	O
melanoma	B-DISEASE
and	O
confirm	O
the	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	O
melanoma	B-DISEASE
Progression	O
of	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
The	O
genetic	O
basis	O
of	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
UTR	O
of	O
the	O
DM	B-DISEASE
protein	O
kinase	O
gene	O
on	O
chromosome	B-DISEASE
19	I-DISEASE
One	O
of	O
the	O
principal	O
features	O
of	O
the	O
DM	B-DISEASE
This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	B-DISEASE
In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B-DISEASE
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
Aspartylglucosaminuria	B-DISEASE
Aspartylglucosaminuria	B-DISEASE
(	O
AGU	O
)	O
is	O
a	O
rare	O
disorder	O
of	O
glycoprotein	O
metabolism	B-DISEASE
The	O
clinical	O
diagnosis	O
of	O
AGU	O
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	B-DISEASE
However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	B-DISEASE
,	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	B-DISEASE
Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
In	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
(	O
A	O
-	O
T	O
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	O
recessive	O
syndrome	B-DISEASE
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B-DISEASE
Heterozygotes	O
for	O
the	O
ATM	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
A	O
-	O
T	O
but	O
may	O
be	O
cancer	B-DISEASE
In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	O
and	O
sporadic	O
cancers	B-DISEASE
aimed	O
at	B-DISEASE
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	B-DISEASE
Ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	B-DISEASE
,	O
such	O
as	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
The	O
von	O
Hippel	O
-	O
Lindau	O
tumor	B-DISEASE
The	O
inactivation	O
of	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
tumor	B-DISEASE
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	O
cancer	B-DISEASE
syndrome	B-DISEASE
and	O
is	O
associated	O
with	O
sporadic	O
renal	B-DISEASE
The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B-DISEASE
Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	O
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	O
cancer	B-DISEASE
We	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
-	O
type	O
VHL	O
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B-DISEASE
This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	O
,	O
implicating	O
VHL	O
as	O
the	O
first	O
tumor	B-DISEASE
Piebaldism	B-DISEASE
with	O
deafness	B-DISEASE
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome	B-DISEASE
In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	B-DISEASE
and	O
profound	O
congenital	B-DISEASE
sensorineural	O
deafness	B-DISEASE
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	B-DISEASE
Though	O
auditory	O
anomalies	O
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
mutations	O
,	O
deafness	B-DISEASE
is	O
not	O
typical	O
in	O
human	O
piebaldism	B-DISEASE
Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	O
deafness	B-DISEASE
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B-DISEASE
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B-DISEASE
and	O
the	O
various	O
forms	O
of	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
Cycloheximide	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	O
benign	O
epidermolysis	B-DISEASE
bullosa	I-DISEASE
Patients	O
with	O
generalized	O
atrophic	O
benign	O
epidermolysis	B-DISEASE
bullosa	I-DISEASE
This	O
report	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	O
benign	O
epidermolysis	B-DISEASE
bullosa	I-DISEASE
Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	B-DISEASE
This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	B-DISEASE
These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	B-DISEASE
A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	O
benign	O
epidermolysis	B-DISEASE
bullosa	I-DISEASE
Patients	O
with	O
generalized	O
atrophic	O
benign	O
epidermolysis	B-DISEASE
bullosa	I-DISEASE
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	O
epidermolysis	B-DISEASE
bullosa	I-DISEASE
,	O
have	O
generalized	O
blistering	O
,	O
nail	O
dystrophy	O
,	O
patchy	O
alopecia	B-DISEASE
,	O
and	O
dental	O
abnormalities	B-DISEASE
Skin	B-DISEASE
Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	O
benign	O
epidermolysis	B-DISEASE
bullosa	I-DISEASE
Three	O
families	O
shared	O
microsatellite	O
polymorphisms	O
covering	O
at	B-DISEASE
most	O
19	O
cM	B-DISEASE
Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	O
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	B-DISEASE
ATM	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	B-DISEASE
,	O
lymphoma	B-DISEASE
,	O
and	O
breast	B-DISEASE
cancer	I-DISEASE
We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B-DISEASE
degeneration	I-DISEASE
We	O
report	O
,	O
in	O
two	O
A	O
-	O
T	O
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
a	O
less	O
severe	O
A	O
-	O
T	O
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	B-DISEASE
degeneration	I-DISEASE
This	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
at	B-DISEASE
In	O
addition	O
,	O
we	O
have	O
studied	O
18	O
A	O
-	O
T	O
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B-DISEASE
,	O
lymphoma	B-DISEASE
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B-DISEASE
lymphoma	I-DISEASE
The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	B-DISEASE
In	O
most	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
the	O
disease	B-DISEASE
was	O
congenital	B-DISEASE
Preliminary	O
in	O
vivo	O
footprinting	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	B-DISEASE
The	O
hemochromatosis	B-DISEASE
We	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B-DISEASE
hemochromatosis	I-DISEASE
Studies	O
on	O
cell	O
-	O
associated	O
transferrin	O
at	B-DISEASE
Furthermore	O
,	O
at	B-DISEASE
These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	B-DISEASE
hemochromatosis	I-DISEASE
The	O
UBE3A	O
gene	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B-DISEASE
syndrome	I-DISEASE
patients	O
who	O
lack	O
15q11	O
-	O
q13	O
deletions	O
or	O
chromosome	B-DISEASE
15	I-DISEASE
paternal	O
uniparental	B-DISEASE
disomy	I-DISEASE
Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	O
disease	B-DISEASE
and	O
Bannayan	O
-	O
Zonana	O
syndrome	B-DISEASE
,	O
two	O
hamartoma	B-DISEASE
3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	B-DISEASE
Somatic	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	O
breast	O
,	O
brain	O
,	O
prostate	O
and	O
kidney	B-DISEASE
cancer	I-DISEASE
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	O
such	O
as	O
endometrial	O
carcinomas	O
,	O
malignant	O
melanoma	B-DISEASE
and	O
thyroid	B-DISEASE
In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B-DISEASE
syndromes	O
Cowden	O
disease	B-DISEASE
(	O
CD	O
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	O
-	O
Zonana	O
(	O
BZS	O
)	O
or	O
Ruvalcaba	O
-	O
Riley	O
-	O
Smith	O
syndrome	B-DISEASE
The	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	O
families	O
with	O
breast	O
disease	B-DISEASE
Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	O
breast	O
disease	B-DISEASE
Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	B-DISEASE
,	O
breast	O
,	O
skin	B-DISEASE
Molecular	O
defects	O
leading	O
to	O
human	O
complement	O
component	O
C6	B-DISEASE
deficiency	I-DISEASE
Complement	O
component	O
C6	B-DISEASE
deficiency	I-DISEASE
(	O
C6D	O
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
male	O
with	O
meningococcal	O
meningitis	B-DISEASE
The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	O
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B-DISEASE
or	O
other	O
neisserial	O
infection	B-DISEASE
Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	B-DISEASE
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	B-DISEASE
anomaly	I-DISEASE
,	O
with	O
congenital	B-DISEASE
cataracts	I-DISEASE
,	O
with	O
autosomal	O
dominant	O
keratitis	B-DISEASE
,	O
and	O
with	O
isolated	O
foveal	B-DISEASE
hypoplasia	I-DISEASE
No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B-DISEASE
Twenty	O
-	O
eight	O
percent	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	B-DISEASE
Genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	B-DISEASE
cancer	I-DISEASE
The	O
Breast	B-DISEASE
Cancer	I-DISEASE
The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	O
breast	B-DISEASE
cancer	I-DISEASE
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	B-DISEASE
least	O
four	O
cases	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
collected	O
by	O
the	O
Breast	B-DISEASE
Cancer	I-DISEASE
Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	O
or	O
other	O
cancers	B-DISEASE
Overall	O
,	O
disease	B-DISEASE
The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
breast	B-DISEASE
-	I-DISEASE
ovarian	I-DISEASE
cancer	I-DISEASE
Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	O
and	O
female	O
breast	B-DISEASE
cancer	I-DISEASE
The	O
largest	O
proportion	O
(	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B-DISEASE
cancer	I-DISEASE
Among	O
those	O
families	O
with	O
disease	B-DISEASE
The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
The	O
corresponding	O
ovarian	B-DISEASE
cancer	I-DISEASE
The	O
lifetime	O
risk	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
Eye	O
movement	O
abnormalities	B-DISEASE
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B-DISEASE
ataxia	I-DISEASE
We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	O
ataxias	O
type	O
I	O
spinocerebellar	B-DISEASE
ataxias	I-DISEASE
1	O
and	O
2	O
(	O
SCA1	O
,	O
n	O
=	O
11	O
;	O
SCA2	O
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	O
/	O
Machado	B-DISEASE
-	I-DISEASE
Joseph	I-DISEASE
disease	I-DISEASE
The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	B-DISEASE
disease	B-DISEASE
In	O
SCA3	O
,	O
gaze	O
-	O
evoked	O
nystagmus	B-DISEASE
Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	O
-	O
evoked	O
nystagmus	B-DISEASE
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	O
,	O
90	O
%	O
of	O
the	O
SCA2	O
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	O
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	O
,	O
SCA2	O
,	O
and	O
SCA3	O
at	B-DISEASE
early	O
clinical	O
stages	O
of	O
the	O
diseases	B-DISEASE
Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B-DISEASE
ventricular	I-DISEASE
fibrillation	I-DISEASE
Ventricular	B-DISEASE
fibrillation	I-DISEASE
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	B-DISEASE
In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B-DISEASE
ventricular	I-DISEASE
fibrillation	I-DISEASE
Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	O
death	B-DISEASE
Identification	O
of	O
constitutional	O
WT1	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	B-DISEASE
diffuse	I-DISEASE
mesangial	I-DISEASE
sclerosis	I-DISEASE
Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
a	O
zinc	B-DISEASE
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	B-DISEASE
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
(	O
DDS	O
)	O
,	O
or	O
diffuse	B-DISEASE
mesangial	I-DISEASE
sclerosis	I-DISEASE
(	O
DMS	O
)	O
associated	O
with	O
pseudohermaphroditism	B-DISEASE
and	O
/	O
or	O
Wilms	B-DISEASE
tumor	I-DISEASE
Most	O
mutations	O
in	O
DDS	O
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	B-DISEASE
finger	O
2	O
or	O
zinc	B-DISEASE
We	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	O
DMS	O
(	O
IDMS	O
)	O
,	O
10	O
with	O
DDS	O
,	O
and	O
4	O
with	O
urogenital	B-DISEASE
abnormalities	I-DISEASE
One	O
male	O
and	O
two	O
female	O
IDMS	O
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty	B-DISEASE
No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	O
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	B-DISEASE
The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	O
breast	O
and	O
ovarian	B-DISEASE
cancer	I-DISEASE
All	O
tested	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
pattern	O
at	B-DISEASE
BRCA1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast	O
/	O
ovarian	B-DISEASE
cancer	I-DISEASE
We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	B-DISEASE
However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	B-DISEASE
Crystal	O
structure	O
of	O
the	O
hemochromatosis	B-DISEASE
HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	O
-	O
overload	O
disease	B-DISEASE
hereditary	B-DISEASE
hemochromatosis	I-DISEASE
HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
implicating	O
HFE	O
in	O
iron	O
metabolism	B-DISEASE
6	O
A	O
crystal	O
structure	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B-DISEASE
We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	O
at	B-DISEASE
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
but	O
not	O
at	B-DISEASE
Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	O
disease	B-DISEASE
Four	O
mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	O
disease	B-DISEASE
Since	O
a	O
mutation	O
at	B-DISEASE
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	O
disease	B-DISEASE
Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
Myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B-DISEASE
One	O
model	O
of	O
DM	B-DISEASE
Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	B-DISEASE
Altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B-DISEASE
Identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	O
kindreds	O
with	O
familial	O
neurohypophyseal	O
diabetes	B-DISEASE
insipidus	I-DISEASE
Familial	O
neurohypophyseal	O
diabetes	B-DISEASE
insipidus	I-DISEASE
(	O
FNDI	O
)	O
is	O
an	O
autosomal	O
dominant	O
disease	B-DISEASE
In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	B-DISEASE
In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	B-DISEASE
Genetic	O
heterogeneity	O
of	O
Saethre	O
-	O
Chotzen	O
syndrome	B-DISEASE
Thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	O
-	O
Chotzen	O
syndrome	B-DISEASE
,	O
a	O
common	O
autosomal	O
dominant	O
condition	O
of	O
craniosynostosis	B-DISEASE
To	O
date	O
,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	O
-	O
Chotzen	O
syndrome	B-DISEASE
The	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations	O
,	O
are	O
coronal	B-DISEASE
synostosis	I-DISEASE
,	O
brachycephaly	B-DISEASE
,	O
low	O
frontal	O
hairline	O
,	O
facial	B-DISEASE
asymmetry	I-DISEASE
,	O
ptosis	B-DISEASE
,	O
hypertelorism	B-DISEASE
Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B-DISEASE
syndrome	I-DISEASE
Angelman	B-DISEASE
syndrome	I-DISEASE
(	O
AS	O
)	O
is	O
caused	O
by	O
chromosome	O
15q11	O
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B-DISEASE
disomy	I-DISEASE
The	O
hemochromatosis	B-DISEASE
Hemochromatosis	B-DISEASE
,	O
the	O
inherited	O
disorder	O
of	O
iron	O
metabolism	B-DISEASE
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B-DISEASE
overload	I-DISEASE
and	O
premature	O
death	B-DISEASE
The	O
hemochromatosis	B-DISEASE
Although	O
hemochromatosis	B-DISEASE
187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
at	B-DISEASE
Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
Germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	B-DISEASE
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
(	O
AAPC	O
)	O
,	O
a	O
variant	O
of	O
familial	B-DISEASE
adenomatous	I-DISEASE
polyposis	I-DISEASE
(	O
FAP	B-DISEASE
AAPC	O
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	O
adenomas	O
and	O
a	O
later	O
onset	O
of	O
colorectal	B-DISEASE
cancer	I-DISEASE
Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	O
gene	O
(	O
1	O
)	O
at	B-DISEASE
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	B-DISEASE
In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	O
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	B-DISEASE
No	O
desmoid	B-DISEASE
tumors	I-DISEASE
This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B-DISEASE
Wilms	B-DISEASE
'	I-DISEASE
tumor	I-DISEASE
Products	O
of	O
steroidogenic	O
factor	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B-DISEASE
tumor	I-DISEASE
1	I-DISEASE
In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	O
pseudohermaphroditism	B-DISEASE
in	O
Denys	B-DISEASE
-	I-DISEASE
Drash	I-DISEASE
syndrome	I-DISEASE
A	O
mouse	O
model	O
for	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	O
disease	B-DISEASE
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	B-DISEASE
-	O
causing	O
ATM	O
mutations	O
in	O
Japanese	O
A	O
-	O
T	O
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	B-DISEASE
The	O
4612del165	O
mutations	O
in	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T	O
-	O
-	O
>	O
A	O
substitution	O
at	B-DISEASE
W474C	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
is	O
associated	O
with	O
subacute	O
G	O
(	O
M2	O
)	O
gangliosidosis	B-DISEASE
Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B-DISEASE
-	I-DISEASE
Sachs	I-DISEASE
disease	I-DISEASE
(	O
TSD	O
)	O
,	O
the	O
fatal	O
infantile	O
form	O
of	O
G	O
(	O
M2	O
)	O
gangliosidosis	B-DISEASE
We	O
identified	O
a	O
1422	O
G	O
-	O
-	O
>	O
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
G	O
(	O
M2	O
)	O
gangliosidosis	B-DISEASE
On	O
the	O
second	O
maternally	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	B-DISEASE
The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	B-DISEASE
Two	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B-DISEASE
syndrome	I-DISEASE
Pendred	B-DISEASE
syndrome	I-DISEASE
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
early	O
childhood	O
deafness	B-DISEASE
and	O
goiter	B-DISEASE
A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	B-DISEASE
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	B-DISEASE
The	O
identification	O
of	O
two	O
frequent	O
PDS	O
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B-DISEASE
syndrome	I-DISEASE
Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	O
gene	O
results	O
in	O
X	O
-	O
linked	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
X	O
-	O
linked	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
(	O
XLDCM	O
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	O
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	O
involvement	O
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	O
myopathy	B-DISEASE
To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	O
muscular	B-DISEASE
dystrophy	I-DISEASE
Severe	O
early	O
-	O
onset	O
obesity	B-DISEASE
,	O
adrenal	B-DISEASE
insufficiency	I-DISEASE
While	O
a	O
few	O
cases	O
of	O
isolated	O
ACTH	B-DISEASE
deficiency	I-DISEASE
Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	O
(	O
MC4	O
-	O
R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	O
human	O
obesity	B-DISEASE
to	O
chromosome	B-DISEASE
2	I-DISEASE
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	O
human	O
obesity	B-DISEASE
The	O
dual	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	B-DISEASE
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	B-DISEASE
deficiency	I-DISEASE
These	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	O
defect	O
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	O
endocrine	O
disorder	O
resulting	O
in	O
early	O
-	O
onset	O
obesity	B-DISEASE
,	O
adrenal	B-DISEASE
insufficiency	I-DISEASE
Phenylketonuria	B-DISEASE
(	O
PKU	B-DISEASE
)	O
and	O
mild	O
hyperphenylalaninemia	B-DISEASE
In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B-DISEASE
Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	B-DISEASE
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	B-DISEASE
The	O
trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B-DISEASE
and	O
other	O
human	O
genetic	B-DISEASE
diseases	I-DISEASE
We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	B-DISEASE
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B-DISEASE
As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
DM	B-DISEASE
A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B-DISEASE
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B-DISEASE
We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B-DISEASE
In	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	O
tumors	B-DISEASE
A	O
single	O
band	O
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	B-DISEASE
Analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	B-DISEASE
Maternal	O
disomy	O
and	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	B-DISEASE
Maternal	O
uniparental	B-DISEASE
disomy	I-DISEASE
(	O
UPD	O
)	O
for	O
chromosome	B-DISEASE
15	I-DISEASE
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
Prader	B-DISEASE
-	I-DISEASE
Willi	I-DISEASE
syndrome	I-DISEASE
We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	O
disomy	O
15	O
in	O
PWS	O
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	B-DISEASE
for	O
chromosome	B-DISEASE
15	I-DISEASE
The	O
patient	O
(	O
J	O
.	O
B	O
.	O
)	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
white	O
male	O
with	O
PWS	O
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	B-DISEASE
15	I-DISEASE
Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	O
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	B-DISEASE
3	I-DISEASE
Methylation	O
analysis	O
at	B-DISEASE
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	B-DISEASE
15	I-DISEASE
Maternal	O
disomy	O
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	B-DISEASE
Uniparental	B-DISEASE
disomy	I-DISEASE
Schwartz	O
-	O
Jampel	O
syndrome	B-DISEASE
type	O
2	O
and	O
Stuve	B-DISEASE
-	I-DISEASE
Wiedemann	I-DISEASE
syndrome	I-DISEASE
Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	O
-	O
Jampel	O
syndrome	B-DISEASE
(	O
SJS	O
)	O
of	O
myotonia	B-DISEASE
and	O
skeletal	B-DISEASE
dysplasia	I-DISEASE
This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
Stuve	B-DISEASE
-	I-DISEASE
Wiedemann	I-DISEASE
syndrome	I-DISEASE
(	O
SWS	O
)	O
,	O
which	O
comprises	O
campomelia	O
at	B-DISEASE
birth	O
with	O
skeletal	B-DISEASE
dysplasia	I-DISEASE
,	O
contractures	B-DISEASE
,	O
and	O
early	O
death	B-DISEASE
To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	O
type	O
2	O
at	B-DISEASE
age	O
10	O
years	O
and	O
another	O
with	O
SWS	O
at	B-DISEASE
Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	O
or	O
SWS	O
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	O
disorder	O
(	O
with	O
congenital	B-DISEASE
joint	O
contractures	B-DISEASE
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B-DISEASE
,	O
and	O
frequent	O
death	B-DISEASE
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	O
-	O
metaphyseal	O
skeletal	B-DISEASE
dysplasia	I-DISEASE
The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B-DISEASE
dysplasia	I-DISEASE
A	O
mouse	O
model	O
of	O
severe	O
von	B-DISEASE
Willebrand	I-DISEASE
disease	I-DISEASE
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	B-DISEASE
von	B-DISEASE
Willebrand	I-DISEASE
factor	I-DISEASE
(	O
vWf	O
)	O
deficiency	O
causes	O
severe	O
von	B-DISEASE
Willebrand	I-DISEASE
disease	I-DISEASE
We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	B-DISEASE
vWf	O
-	O
deficient	O
mice	O
appeared	O
normal	O
at	B-DISEASE
The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	B-DISEASE
bleeding	I-DISEASE
time	I-DISEASE
and	O
spontaneous	O
bleeding	B-DISEASE
As	O
in	O
the	O
human	O
disease	B-DISEASE
Defective	O
thrombosis	B-DISEASE
We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B-DISEASE
Willebrand	I-DISEASE
disease	I-DISEASE
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	B-DISEASE
models	I-DISEASE
Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	O
ovarian	B-DISEASE
cancer	I-DISEASE
Hereditary	O
Ovarian	B-DISEASE
Cancer	I-DISEASE
BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
Oral	O
contraceptives	O
protect	O
against	O
ovarian	B-DISEASE
cancer	I-DISEASE
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	O
forms	O
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	O
ovarian	B-DISEASE
cancer	I-DISEASE
RESULTS	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B-DISEASE
cancer	I-DISEASE
Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B-DISEASE
cancer	I-DISEASE
CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B-DISEASE
We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B-DISEASE
The	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	O
disease	B-DISEASE
His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B-DISEASE
in	O
the	O
bilateral	O
cerebellar	O
hemispheres	O
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	B-DISEASE
Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	O
C9	B-DISEASE
deficiency	I-DISEASE
We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B-DISEASE
deficiency	I-DISEASE
in	O
four	O
Japanese	O
C9	O
-	O
deficient	O
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	O
meningitis	B-DISEASE
Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	B-DISEASE
)	O
at	B-DISEASE
The	O
common	O
mutation	O
at	B-DISEASE
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B-DISEASE
deficiency	I-DISEASE
The	O
breast	O
and	O
ovarian	B-DISEASE
cancer	I-DISEASE
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	B-DISEASE
Heterozygous	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B-DISEASE
,	O
Peters	B-DISEASE
anomaly	I-DISEASE
,	O
autosomal	O
dominant	O
keratitis	B-DISEASE
It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B-DISEASE
However	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B-DISEASE
These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B-DISEASE
Reversal	O
of	O
severe	O
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
We	O
describe	O
the	O
outcome	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
VLCAD	B-DISEASE
deficiency	I-DISEASE
who	O
was	O
first	O
seen	O
at	B-DISEASE
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
,	O
hepatomegaly	B-DISEASE
,	O
encephalopathy	B-DISEASE
,	O
and	O
hypotonia	B-DISEASE
Biochemical	O
studies	O
indicated	O
VLCAD	B-DISEASE
deficiency	I-DISEASE
Her	O
ventricular	O
hypertrophy	B-DISEASE
Clinical	O
recognition	O
of	O
VLCAD	B-DISEASE
deficiency	I-DISEASE
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B-DISEASE
A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin	O
-	O
dependent	O
diabetes	B-DISEASE
mellitus	I-DISEASE
Based	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	B-DISEASE
The	O
APC	O
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	O
tumors	B-DISEASE
Classical	O
familial	B-DISEASE
adenomatous	I-DISEASE
polyposis	I-DISEASE
(	O
FAP	B-DISEASE
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	O
dominant	O
disease	B-DISEASE
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	O
adenomas	O
and	O
carcinoma	B-DISEASE
A	O
variant	O
of	O
FAP	B-DISEASE
is	O
attenuated	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
Attenuated	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
patients	O
have	O
"	O
multiple	O
"	O
colorectal	O
adenomas	O
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B-DISEASE
Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	O
has	O
no	O
mutations	O
in	O
the	O
APC	O
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	B-DISEASE
Recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
of	O
APC	O
(	O
I1307K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
risk	O
of	O
colorectal	O
tumors	B-DISEASE
We	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	O
adenomas	O
and	O
/	O
or	O
carcinoma	B-DISEASE
Four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	O
polyps	B-DISEASE
There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
APC	O
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	O
adenomas	O
and	O
carcinoma	B-DISEASE
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B-DISEASE
,	O
and	O
possibly	O
with	O
importance	O
for	O
colorectal	B-DISEASE
cancer	I-DISEASE
Genomic	O
structure	O
of	O
the	O
human	O
congenital	B-DISEASE
chloride	I-DISEASE
diarrhea	I-DISEASE
Congenital	B-DISEASE
chloride	I-DISEASE
diarrhea	I-DISEASE
Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	B-DISEASE
Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H	O
_	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	O
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B-DISEASE
syndrome	I-DISEASE
The	O
APCI1307K	O
allele	O
and	O
cancer	B-DISEASE
Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B-DISEASE
adenomatous	I-DISEASE
polyposis	I-DISEASE
(	O
FAP	B-DISEASE
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
multiple	O
intestinal	B-DISEASE
polyps	I-DISEASE
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B-DISEASE
cancer	I-DISEASE
To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B-DISEASE
Risk	O
of	O
developing	O
colorectal	O
,	O
breast	O
and	O
other	O
cancers	B-DISEASE
Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B-DISEASE
ataxia	I-DISEASE
Friedreich	B-DISEASE
ataxia	I-DISEASE
The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	B-DISEASE
leukodystrophy	I-DISEASE
Deficiency	O
of	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	O
metachromatic	B-DISEASE
leukodystrophy	I-DISEASE
We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	B-DISEASE
Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B-DISEASE
cell	O
carcinoma	B-DISEASE
To	O
discover	O
genes	O
involved	O
in	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
-	O
mediated	O
carcinogenesis	B-DISEASE
,	O
we	O
used	O
renal	B-DISEASE
cell	O
carcinoma	B-DISEASE
Reintroduced	O
wild	O
-	O
type	O
VHL	O
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B-DISEASE
cell	O
carcinoma	B-DISEASE
2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B-DISEASE
Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B-DISEASE
A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
optic	B-DISEASE
atrophy	I-DISEASE
(	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
Wolfram	B-DISEASE
syndrome	I-DISEASE
(	O
WFS	O
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	O
recessive	O
neurodegenerative	B-DISEASE
disorder	I-DISEASE
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	O
-	O
dependent	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
progressive	O
optic	B-DISEASE
atrophy	I-DISEASE
On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	B-DISEASE
Mutations	O
in	O
a	O
novel	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	O
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	B-DISEASE
Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B-DISEASE
BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	O
and	O
/	O
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	O
breast	O
and	O
/	O
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
A	O
novel	O
C	O
to	O
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	O
xanthomatosis	B-DISEASE
As	O
the	O
mutation	O
occurred	O
at	B-DISEASE
Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	B-DISEASE
Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	B-DISEASE
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
mutation	O
at	B-DISEASE
ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	O
recessive	O
disorder	O
ataxia	B-DISEASE
-	O
telangiectasia	B-DISEASE
Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	O
recessive	O
Alport	B-DISEASE
syndrome	I-DISEASE
Autosomal	O
recessive	O
Alport	B-DISEASE
syndrome	I-DISEASE
is	O
a	O
progressive	O
hematuric	O
glomerulonephritis	B-DISEASE
characterized	O
by	O
glomerular	O
basement	O
membrane	O
abnormalities	B-DISEASE
We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	O
recessive	O
Alport	B-DISEASE
syndrome	I-DISEASE
Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	O
and	O
ovarian	B-DISEASE
cancer	I-DISEASE
We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	B-DISEASE
cancer	I-DISEASE
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	O
Canadian	O
breast	B-DISEASE
cancer	I-DISEASE
and	O
breast	O
/	O
ovarian	B-DISEASE
cancer	I-DISEASE
To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B-DISEASE
Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	B-DISEASE
7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
3x	O
greater	O
if	O
there	O
were	O
at	B-DISEASE
least	O
five	O
cases	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
Interestingly	O
,	O
the	O
presence	O
of	O
a	O
breast	B-DISEASE
cancer	I-DISEASE
The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B-DISEASE
cancer	I-DISEASE
and	O
breast	O
/	O
ovarian	B-DISEASE
cancer	I-DISEASE
Are	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B-DISEASE
impairment	I-DISEASE
in	O
Duchenne	O
muscular	B-DISEASE
dystrophy	I-DISEASE
Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	O
muscular	B-DISEASE
dystrophy	I-DISEASE
(	O
DMD	O
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B-DISEASE
impairment	I-DISEASE
Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B-DISEASE
impairment	I-DISEASE
These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	O
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B-DISEASE
impairment	I-DISEASE
I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	O
non	O
-	O
polyposis	B-DISEASE
colorectal	B-DISEASE
cancer	I-DISEASE
We	O
describe	O
a	O
French	O
Canadian	O
hereditary	O
non	O
-	O
polyposis	B-DISEASE
colorectal	B-DISEASE
cancer	I-DISEASE
Interestingly	O
,	O
the	O
I1307K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B-DISEASE
cancer	I-DISEASE
In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	B-DISEASE
Identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	O
coproporphyria	B-DISEASE
Hereditary	O
coproporphyria	B-DISEASE
(	O
HCP	O
)	O
is	O
an	O
autosomal	O
dominant	O
disease	B-DISEASE
Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
demonstrated	O
a	O
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
gene	O
at	B-DISEASE
This	O
mutation	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	B-DISEASE
Human	O
complement	B-DISEASE
factor	I-DISEASE
H	I-DISEASE
deficiency	I-DISEASE
associated	O
with	O
hemolytic	B-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
This	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	O
in	O
the	O
human	O
complement	O
regulatory	O
protein	O
Factor	O
H	O
(	O
FH	B-DISEASE
)	O
in	O
the	O
context	O
of	O
an	O
acute	O
renal	B-DISEASE
disease	B-DISEASE
Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
(	O
HUS	B-DISEASE
Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
Factor	O
H	O
-	O
like	O
protein	O
1	O
(	O
FHL	O
-	O
1	O
)	O
and	O
other	O
FH	B-DISEASE
Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	B-DISEASE
The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	B-DISEASE
Factor	B-DISEASE
H	I-DISEASE
deficiency	I-DISEASE
is	O
the	O
only	O
complement	O
deficiency	O
associated	O
with	O
HUS	B-DISEASE
These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	B-DISEASE
and	O
/	O
or	O
FH	B-DISEASE
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B-DISEASE
Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
The	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	B-DISEASE
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
on	O
DM	B-DISEASE
Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B-DISEASE
To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	B-DISEASE
Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B-DISEASE
To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B-DISEASE
These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B-DISEASE
and	O
Friedreichs	O
ataxia	B-DISEASE
The	O
molecular	O
basis	O
of	O
C6	B-DISEASE
deficiency	I-DISEASE
Meningococcal	O
disease	B-DISEASE
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B-DISEASE
deficiency	I-DISEASE
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	B-DISEASE
A	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	B-DISEASE
high	O
risk	O
for	O
bipolar	B-DISEASE
affective	B-DISEASE
disorder	I-DISEASE
Bipolar	B-DISEASE
affective	B-DISEASE
disorder	I-DISEASE
(	O
BPAD	O
;	O
manic	B-DISEASE
-	I-DISEASE
depressive	I-DISEASE
illness	I-DISEASE
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	B-DISEASE
and	O
/	O
or	O
hypomania	O
interspersed	O
with	O
periods	O
of	O
depression	B-DISEASE
To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
BPAD	O
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	O
disorders	O
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B-DISEASE
We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	B-DISEASE
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-	O
4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	B-DISEASE
These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
BPAD	O
and	O
perhaps	O
other	O
related	O
affective	B-DISEASE
disorders	I-DISEASE
Segregation	O
distortion	O
in	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
Myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
DM	B-DISEASE
)	O
is	O
an	O
autosomal	O
dominant	O
disease	B-DISEASE
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	B-DISEASE
This	O
results	O
in	O
infertility	B-DISEASE
and	O
congenital	B-DISEASE
myotonic	I-DISEASE
dystrophy	I-DISEASE
(	O
CDM	O
)	O
with	O
the	O
disappearance	O
of	O
DM	B-DISEASE
The	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	B-DISEASE
the	O
DM	B-DISEASE
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
DM	B-DISEASE
In	O
a	O
survey	O
of	O
DM	B-DISEASE
Sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
the	O
DM	B-DISEASE
Studies	O
on	O
meiotic	O
drive	O
in	O
DM	B-DISEASE
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	B-DISEASE
the	O
DM	B-DISEASE
locus	O
in	O
non	O
-	O
DM	B-DISEASE
This	O
study	O
provides	O
further	O
evidence	O
that	O
the	O
DM	B-DISEASE
Diagnosis	O
of	O
hemochromatosis	B-DISEASE
If	O
untreated	O
,	O
hemochromatosis	B-DISEASE
can	O
cause	O
serious	O
illness	O
and	O
early	O
death	B-DISEASE
,	O
but	O
the	O
disease	B-DISEASE
Once	O
the	O
diagnosis	O
is	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	B-DISEASE
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B-DISEASE
overload	I-DISEASE
Liver	B-DISEASE
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B-DISEASE
A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B-DISEASE
Currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B-DISEASE
in	O
the	O
family	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease	B-DISEASE
It	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	B-DISEASE
before	O
hepatic	B-DISEASE
cirrhosis	I-DISEASE
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	B-DISEASE
disease	I-DISEASE
Prevalence	O
of	O
the	O
I1307K	O
APC	O
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B-DISEASE
cancer	I-DISEASE
BACKGROUND	O
&	O
AIMS	O
Israeli	O
Jews	O
of	O
European	O
birth	O
,	O
i	O
.	O
e	O
.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
highest	O
colorectal	B-DISEASE
cancer	I-DISEASE
1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B-DISEASE
cancer	I-DISEASE
We	O
assessed	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B-DISEASE
cancer	I-DISEASE
RESULTS	O
In	O
persons	O
at	B-DISEASE
average	O
risk	O
for	O
colorectal	B-DISEASE
cancer	I-DISEASE
4	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	B-DISEASE
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	B-DISEASE
increased	O
cancer	B-DISEASE
CONCLUSIONS	O
The	O
I1307K	O
APC	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal	O
,	O
or	O
other	O
,	O
cancers	B-DISEASE
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	B-DISEASE
cancer	I-DISEASE
Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	O
coproporphyria	B-DISEASE
Hereditary	O
coproporphyria	B-DISEASE
(	O
HC	O
)	O
is	O
an	O
acute	O
hepatic	O
porphyria	B-DISEASE
Clinical	O
manifestations	O
of	O
the	O
disease	B-DISEASE
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	O
dysfunction	O
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infectious	B-DISEASE
diseases	I-DISEASE
Skin	B-DISEASE
Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	B-DISEASE
Coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
metachromatic	B-DISEASE
leukodystrophy	I-DISEASE
In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B-DISEASE
leukodystrophy	I-DISEASE
(	O
MLD	O
)	O
,	O
fatal	O
at	B-DISEASE
The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	B-DISEASE
The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0	O
-	O
type	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	B-DISEASE
The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	B-DISEASE
Our	O
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
MLD	O
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	B-DISEASE
Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0	O
-	O
type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	B-DISEASE
Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	O
malignancy	B-DISEASE
and	O
neurofibromatosis	B-DISEASE
Heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	O
nonpolyposis	O
colorectal	B-DISEASE
cancer	I-DISEASE
The	O
disease	B-DISEASE
susceptibility	I-DISEASE
We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	O
nonpolyposis	O
colorectal	B-DISEASE
cancer	I-DISEASE
family	O
who	O
developed	O
hematological	O
malignancy	B-DISEASE
at	B-DISEASE
a	O
very	O
early	O
age	O
,	O
and	O
at	B-DISEASE
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B-DISEASE
Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B-DISEASE
and	O
/	O
or	O
lymphoma	B-DISEASE
associated	O
with	O
neurofibromatosis	B-DISEASE
Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B-DISEASE
Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B-DISEASE
(	O
congenital	B-DISEASE
The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	B-DISEASE
The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	B-DISEASE
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B-DISEASE
This	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B-DISEASE
Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B-DISEASE
pupillae	I-DISEASE
(	O
displaced	O
pupils	O
)	O
and	O
congenital	B-DISEASE
nystagmus	B-DISEASE
(	O
searching	O
gaze	O
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	B-DISEASE
Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	O
-	O
related	O
disease	B-DISEASE
A	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	O
deficiency	O
and	O
HLA	O
-	O
B	O
at	B-DISEASE
A	O
lod	O
score	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	B-DISEASE
Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B-DISEASE
-	I-DISEASE
Dreifuss	I-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	B-DISEASE
These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	B-DISEASE
Genetic	O
mapping	O
of	O
the	O
copper	B-DISEASE
toxicosis	I-DISEASE
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	B-DISEASE
10	I-DISEASE
The	O
major	O
cause	O
of	O
hepatic	O
copper	O
accumulation	O
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	O
disease	B-DISEASE
The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	O
overload	O
disease	B-DISEASE
non	O
-	O
Indian	O
childhood	O
cirrhosis	B-DISEASE
By	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	B-DISEASE
toxicosis	I-DISEASE
(	O
CT	O
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B-DISEASE
disease	I-DISEASE
Molecular	O
analysis	O
of	O
the	O
APC	O
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B-DISEASE
and	O
evidence	O
for	O
the	O
role	O
of	O
APC	O
amino	O
acid	O
changes	O
in	O
colorectal	B-DISEASE
cancer	I-DISEASE
BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B-DISEASE
cancer	I-DISEASE
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B-DISEASE
adenomatous	I-DISEASE
polyposis	I-DISEASE
(	O
FAP	B-DISEASE
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B-DISEASE
polyposis	I-DISEASE
coli	I-DISEASE
In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	O
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	O
mutations	O
in	O
non	O
-	O
FAP	B-DISEASE
colorectal	B-DISEASE
cancer	I-DISEASE
METHODS	O
The	O
APC	O
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B-DISEASE
and	O
15	O
non	O
-	O
FAP	B-DISEASE
colorectal	B-DISEASE
cancer	I-DISEASE
RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B-DISEASE
Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	B-DISEASE
group	O
of	O
colorectal	B-DISEASE
cancer	I-DISEASE
Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B-DISEASE
This	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
FAP	B-DISEASE
and	O
non	O
-	O
FAP	B-DISEASE
colorectal	B-DISEASE
cancer	I-DISEASE
Inherited	O
colorectal	O
polyposis	B-DISEASE
and	O
cancer	B-DISEASE
Germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	O
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	O
tumor	B-DISEASE
formation	O
in	O
familial	B-DISEASE
adenomatous	I-DISEASE
polyposis	I-DISEASE
syndrome	B-DISEASE
and	O
sporadic	O
colorectal	O
carcinogenesis	B-DISEASE
Recently	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	B-DISEASE
To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	O
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	B-DISEASE
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B-DISEASE
polyps	I-DISEASE
and	O
.	O
or	O
colorectal	B-DISEASE
cancer	I-DISEASE
Furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
APC	O
I1307K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	O
and	O
colorectal	O
cancers	B-DISEASE
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	B-DISEASE
We	O
conclude	O
that	O
the	O
APC	O
I1307K	O
variant	O
leads	O
to	O
increased	O
adenoma	B-DISEASE
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
-	O
4	O
%	O
of	O
all	O
Ashkenazi	O
Jewish	O
colorectal	B-DISEASE
cancer	I-DISEASE
The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B-DISEASE
cancer	I-DISEASE
Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumour	O
-	O
suppressor	O
gene	O
and	O
hereditary	O
breast	O
and	O
ovarian	B-DISEASE
cancer	I-DISEASE
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
non	O
-	O
familial	O
cancers	B-DISEASE
BRCA1	O
mutations	O
are	O
rare	O
in	O
sporadic	O
cancers	B-DISEASE
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	O
non	O
-	O
familial	O
breast	O
and	O
ovarian	O
cancers	B-DISEASE
These	O
reagents	O
detect	O
a	O
220	O
-	O
kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
derived	O
from	O
breast	O
malignancies	B-DISEASE
Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	O
lobular	O
cancers	B-DISEASE
Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	O
carcinomas	O
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	O
breast	O
cancers	B-DISEASE
